Quidel Stock Price, News & Analysis

QuidelOrtho Corporation (Nasdaq: QDEL) reported a 36% increase in fourth quarter revenue of $866.5 million, up from $636.9 million in Q4 2021. For the full year, revenue reached $3.27 billion, a 92% increase driven by Point of Care and Molecular Diagnostics, despite a decline in Labs due to China lockdowns. The fourth quarter GAAP EPS decreased to $0.45, down from $6.85 YoY, while adjusted EPS fell to $1.76, a 66% decline. The company anticipates strong integration progress and growth opportunities in 2023, providing 2023 financial guidance.

QuidelOrtho Corporation (Nasdaq: QDEL) announced preliminary unaudited revenue results for Q4 and FY 2022. Q4 revenues are projected between $853 million and $868 million, with COVID-19 product revenues expected between $124 million and $134 million. For FY 2022, total revenues are anticipated to be between $4,038 million and $4,053 million, marking a significant 502% increase on a GAAP basis. The company emphasizes strong growth in Molecular Diagnostics and Point of Care segments.

QuidelOrtho Corporation (Nasdaq: QDEL) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023, at 9:00 a.m. PST / 12:00 p.m. EST. The presentation will be accessible via a live webcast on QuidelOrtho’s Investor Relations page. QuidelOrtho, a leader in in vitro diagnostics, focuses on innovative technologies for healthcare diagnostics, enhancing patient outcomes globally.

QuidelOrtho Corporation (Nasdaq: QDEL) announced that Health Canada has approved the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test on the Quidel Triage MeterPro platform. This assay, able to provide results in under 20 minutes, enhances the diagnosis of myocardial infarction with high sensitivity and precision. As the first of its kind on a compact analyzer in Canada, it promises faster patient care and improved emergency department efficiency. QuidelOrtho aims to elevate diagnostic testing and patient outcomes.

QuidelOrtho Corporation (Nasdaq: QDEL) announced a joint venture with Runda Medical to develop and manufacture assays for the VITROS® platform in China. This partnership aims to enhance QuidelOrtho's assay menu and accelerate market entry in the fast-growing region. The JV leverages local manufacturing capabilities and expertise to improve efficiencies in assay production. Both companies will share profits from the jointly developed products, with broader assay development anticipated to start in early 2023.

QuidelOrtho Corporation (Nasdaq: QDEL) announces the appointment of Kenneth F. Buechler as non-executive Chairman effective December 11, 2022, and Douglas Bryant as President while retaining his CEO role. This governance change aims to enhance oversight. The board highlights the company's growth post-merger with Ortho Clinical Diagnostics, focusing on disease-specific diagnostics and expanding testing capabilities. The leadership team includes newly appointed Executive Vice Presidents, Robert J. Bujarski and Michael S. Iskra. This strategic direction positions QuidelOrtho for future success in the IVD market.

QuidelOrtho Corporation (Nasdaq: QDEL) will host its inaugural Investor Day on December 13, 2022, at 1:00 p.m. ET in New York City. This event follows the merger of Quidel Corporation and Ortho Clinical Diagnostics in May 2022. Executive presentations will cover the company's strategic growth initiatives, integration efforts, and financial outlook, along with interactive Q&A sessions. Interested parties can register and access the live webcast on QuidelOrtho's Investor Relations page.

QuidelOrtho Corporation (QDEL) reported Q3 2022 revenue of $783.8 million, a 54% increase from Q3 2021's $509.8 million. However, on a constant currency basis, revenue fell 21.8%. GAAP EPS dropped to $0.28 from $5.08 year-over-year. Adjusted EPS decreased to $1.85 from $4.01, reflecting diminished COVID-19 revenue. The company emphasizes the successful integration of operations post-business combination in May 2022. Future guidance will be updated following the earnings call scheduled for today.

QuidelOrtho Corporation (NASDAQ: QDEL) announced its preliminary revenue results for Q3 2022, estimating total revenues between $782 million and $785 million. COVID-19 product revenue is projected at approximately $171 million, while non-COVID-19 product revenue ranges from $611 million to $614 million. The company cites strong retail demand and an unexpected government order as key drivers. Further financial details will be disclosed in a conference call on November 2, 2022.